CABOZANTINIB

Brand name:

• Cabometyx®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Advanced non-clear cell variant renal cell carcinoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to existing listing (Category 2)

Comment:

--

Submission sponsor:

Ipsen Pty Ltd

Other PBAC consideration:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

09/04/2024

Lodgement of required documentation:

18/04/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 15/07/2024

Status:

Finalised

Government processes:

Commenced on 15/07/2024

Medicine listed on the PBS:

01/09/2024 (see PBS schedule)

---